Breo Ellipta Inhaler Flashcards

Questions and Answers

What is the generic name of Breo Ellipta?

fluticasone furoate/vilanterol

What is the dosage of Breo Ellipta?

DPI: 100 mcg fluticasone/25 mcg vilanterol and 200 mcg fluticasone/25 mcg vilanterol; inhalation; 1 inhalation daily, 24 hr duration

What classification does Breo Ellipta fall under?

Corticosteroid/LABA Anticholinergic

What receptor sites does Breo Ellipta target?

Anti-inflammatory and Beta 2 Signup and view all the answers

What are the indications for using Breo Ellipta?

Maintenance treatment of COPD and asthma for patients 18 years and older Signup and view all the answers

What are the contraindications for Breo Ellipta?

Acute bronchospasm. Long-term SABA and LABA use is not recommended. Use lowest effective dose. Always rinse mouth after inhalation. Monitor patients with cardiac problems closely. Chronic lung disease patients may be less responsive. Signup and view all the answers

What hazards are associated with Breo Ellipta?

Oropharyngeal fungal infection, dysphonia, cough, bronchoconstriction, HPA axis suppression, and growth restriction. Signup and view all the answers

What is the duration of action of Breo Ellipta?

24 hrs Signup and view all the answers

What should a patient do after using corticosteroids?

Rinse your mouth out with water to prevent thrush. Signup and view all the answers

What kind of inhaler is Breo Ellipta?

DPI Signup and view all the answers

Study Notes

Breo Ellipta Overview

Generic name: Fluticasone furoate/vilanterol
Formulation: Dry powder inhaler (DPI)

Dosage Information

Available strengths: 100 mcg fluticasone/25 mcg vilanterol and 200 mcg fluticasone/25 mcg vilanterol
Administration: 1 inhalation daily for 24-hour duration

Classification

Type: Combination corticosteroid and long-acting beta-agonist (LABA)
Mechanism: Anticholinergic properties

Receptor Interaction

Acts on anti-inflammatory receptors and Beta-2 adrenergic receptors

Clinical Indications

Indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 18 years and older

Contraindications

Not suitable for acute bronchospasm
Long-term use of short-acting beta agonists (SABAs) and LABAs is not recommended
Use the lowest effective dose; always rinse mouth post-inhalation
Special caution for patients with existing cardiac issues and chronic lung diseases

Potential Hazards

Risks include oropharyngeal fungal infections, dysphonia, cough, and bronchoconstriction
Prolonged use can lead to HPA axis suppression and growth restriction in children
Monitoring of pulse rate is advised due to cardiac effects linked to beta agonist activity

Duration of Action

Provides relief for up to 24 hours

Post-Use Instructions

Patients should rinse their mouths with water after using corticosteroids to prevent oral thrush

Inhaler Type

Administered via a dry powder inhaler (DPI)

Description

Test your knowledge of the Breo Ellipta inhaler, including its generic name, dosage details, and classification. These flashcards provide essential information to enhance your understanding of this medication's properties and usage.